[14C]CCX168
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Trial Timeline
Oct 20, 2014 → Dec 5, 2014
NCT ID
NCT06004960About [14C]CCX168
[14C]CCX168 is a phase 1 stage product being developed by Amgen for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06004960. Target conditions include Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06004960 | Phase 1 | Completed |
Competing Products
5 competing products in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 52 |
| Rituximab + Azathioprine | Roche | Phase 3 | 77 |
| CCX168 | Amgen | Phase 1 | 32 |
| CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin | Amgen | Phase 1 | 32 |
| CCX168 + Placebo | Amgen | Phase 1 | 32 |